Our vision

Lightning API was founded with a vision to bring accurate, honest insights with the goal to accelerate patient access to new and beneficial health technologies, drawing on experience and networks to become an ethical partner for the life sciences industry

 

Our team has extensive experience across the pharmaceutical industry, government and strategic consultancy, with a commitment to aligning commercial objectives with evidence and value demonstration for healthcare technologies

Our core principle is to facilitate direct access to the right insight, at the right time to support healthcare innovation and timely patient access

 

Meet the team

 
Lightning blue.jpg
F. David Alcraft,  Chairman

F. David Alcraft, Chairman

Fiona Paton,  Director

Fiona Paton, Director

Andrew Satherley,  Joint Managing Director

Andrew Satherley, Joint Managing Director

James Whitehouse,  Joint Managing Director

James Whitehouse, Joint Managing Director

Jim Furniss,  Executive advisor EU

Jim Furniss, Executive advisor EU

Pete Carr,  Executive Advisor Industry

Pete Carr, Executive Advisor Industry

Pete Conway,  Executive Advisor Industry

Pete Conway, Executive Advisor Industry

"I am using my experience to establish, with my colleagues, an efficient platform for product pricing to ensure timely access for patients.”

"I am using my experience to establish, with my colleagues, an efficient platform for product pricing to ensure timely access for patients.”

F. David Alcraft, Chairman

As Chairman of Bridgehead International, an international access consultancy now part of GfK, David has spent the last two decades championing an effective dialogue between industry and payers. He is concerned that innovations should find their right place in the diagnosis and treatment of patients and that benefits from research are fully realised. 

"I see a real need to improve the efficiency of collection and analysis of market access data, from rapid early insights to in-depth studies"

"I see a real need to improve the efficiency of collection and analysis of market access data, from rapid early insights to in-depth studies"

Fiona Paton, Director

As Founder and Director of Bridgehead International, an international pricing consultancy divested to GfK, Fiona helped clients to identify, assess and adopt innovative technologies.   She uses her experience to support the development of new drugs and medical devices for the benefit of innovators, health systems and patients.

“I am committed to supporting the development of healthcare innovation with rapid access to strategic insight”

“I am committed to supporting the development of healthcare innovation with rapid access to strategic insight”

Andrew Satherley, Joint Managing Director

Most recently, Andrew  was a Managing Consultant with the Payer Strategy Team at Evidera, with responsibility for the leadership and delivery of global pricing and market access strategies and value communication materials for new medicines. Andrew has worked across a range of disease areas, with extensive oncology experience (including orphan indications). Recent engagements include payer research to inform global pricing strategies (including reference pricing), organisation of advisory boards and simulated payer negotiations, stakeholder mapping and value communication tool development (and testing), and leadership of clinical/economic evidence development plans and HTA scoping. Andrew also lead the Evidera Policy Trends team, with responsibility for reviewing market access policy updates across EU5, Australia, Brazil, China & US. Andrew obtained his MSc Health Economics from the University of York (receiving the Health Economics Prize 2011), and has lead a policy review at the Nova School of Business and Economics, Lisbon, regarding European Commission incentives for the development of orphan drugs.

“I am driven by striking a fair balance between demand and supply in healthcare systems”

“I am driven by striking a fair balance between demand and supply in healthcare systems”

James Whitehouse, Joint Managing Director

Previously working in commissioning for a large hospital provider in the NHS James moved over to market access consultancy working on a variety of access projects including pricing, reimbursement, payer engagement, health economic modelling, due diligence, advisory boards, clinical trial support and payer research. Most recently James has been working as a global market access lead within the pharmaceutical industry, responsible for assets in both hepatology and oncology with the latter from pre-launch to launch planning and execution. James has been responsible for pricing strategy, reimbursement and HTA across Europe, HEOR strategy, payer engagement tools/ rollout, life cycle management and due diligence of potential new assets. James has led and supported on a number of successful HTA submissions in Europe. More recently James has also supported wider commercial activities, leading on brand campaign development and global marketing materials. To date James has worked on over 50 projects spanning across market access and wider commercial support

group.png

Jim Furniss, Executive Advisor (EU)

Jim Furniss is an independent consultant advising companies on market access for pharmaceuticals in Europe, North America and the rest of the world.

Jim was a senior official in the UK Department of Health, responsible for the operation of the Pharmaceutical Price Regulation Scheme and for the NHS drug budget. He was also a member of the European Commission’s Pharmaceutical Pricing Transparency Committee. 

Jim has subsequently spent 20 years in consultancy in the healthcare and pharmaceutical industry, working on a large number of pharmaceutical pricing, reimbursement and market access projects. This has included all major therapy areas, but with an emphasis on oncology and orphan drugs , including treatments for multiple myeloma – specifically lenalidomide and bortezomib.

Pete Carr.png

Pete Carr, Executive Advisor (Industry)

Pete is an experience senior consultant with experience across the spectrum of pharmaceutical commercial activities.

 In Pete's past experience he has been the UK Pharma General Manager (Fujisawa, now Astellas), and EU/Global Managing Director at Pharma Agencies (Grey, ESL, Solaris).

Pete has specific recent UK and EU reimbursement/market access experience across a variety of disease areas and specialises in combining the activities of multiple functions within a life sciences company. 

group.png

Pete Conway, Executive Advisor (Industry)

Pete Conway has 20 years’ experience as both a Health Economist and Market Access Lead in the pharmaceutical industry, working across many therapeutic areas. Initially trained as a hospital/clinical pharmacist in the UK, he further developed his experience working as a Payer Pharmacist in charge of formulary control in a large tertiary care hospital. He then trained and qualified as a Health Economist at Glaxo Welcome working in oncology and diabetes, including the first NICE submission in 1998/9. As Head of EU Market Access at Wyeth, he led nearly 50 HTA submissions across more than 10 brands. He focused on the internationalisation of ENBREL, PREVENAR and EFEXOR, guiding them through multiple pricing and reimbursement processes. Within inflammation, he lead the reimbursement of ENBREL in RA, psoriasis, psoriatic arthritis, and ankylosing spondylitis, and is an author on several papers relating to economics in RA, including the first economic model for biologics in RA. More recently, he was Executive Director, Head of UK Market Access at Grunenthal UK covering health outcomes, market access marketing, government affairs and field-based payer interface specialising in the area of pain. Most recently he was Head of Global Market Access for Norgine Ltd.